Effect of early antiretroviral therapy on sexual behaviors and HIV-1 transmission risk in adults with diverse heterosexual partnership statuses in Côte d’Ivoire

Running head: Effect of early ART on sexual behaviors

Kévin JEAN¹,², Delphine GABILLARD³,⁴ Raoul MOH³, Christine DANEL³, Raïmi FASSASSI⁵, Annabel DESGREES-DU-LOU⁶, Serge EHOLIE³,⁷, France LERT¹,², Xavier ANGLARET³,⁴, Rosemary DRAY-SPIRA¹,²

¹ Epidemiology of Occupational and Social Determinants of Health – Center for Research in Epidemiology and Population Health, INSERM U1018, Villejuif, France;
² UMRS 1018, Université Versailles Saint-Quentin, Villejuif, France;
³ PAC-CI Program, CHU de Treichville, Abidjan, Côte d’Ivoire;
⁴ INSERM U897, Université Bordeaux Segalen, Bordeaux, France;
⁵ Department of Population Research and Development, National Institute of Statistics and Applied Economy, Abidjan, Côte d’Ivoire,
⁶ CEPED (Population and Development Research Center - UMR 196 - Paris Descartes/INED/IRD), IRD (Institut de Recherche pour le Développement), Paris, France
⁷ Service des Maladies Infectieuses et Tropicales, CHU de Treichville, Abidjan, Côte d’Ivoire

Correspondance to: Kévin JEAN
CESP Eq. 11, Hôp. Paul Brousse, Bât 15-16
16 avenue Paul Vaillant Couturier, 94800 Villejuif FRANCE
Tel : +33 1 77 74 74 24
Fax : +33 1 77 74 74 03
kevin.jean@inserm.fr

Text: 3647 words

Abstract: 200 words
Conflict of interest

The authors do not have any commercial or other associations that pose a conflict of interest.

Funding support:

This trial was supported by a grant from the French Agence Nationale de Recherches sur le SIDA et les hépatites virales (ANRS, Paris, France; grants ANRS 12136 and ANRS 12239).

The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.


To whom correspondence and requests for reprints should be addressed:

Kévin JEAN
CESP Eq. 11, Hôp. Paul Brousse, Bât 15-16
16 avenue Paul Vaillant Couturier, 94800 Villejuif FRANCE
Tel : +33 1 77 74 74 24
Fax : +33 1 77 74 74 03
kevin.jean@inserm.fr
**Background:** The effect of early antiretroviral therapy (ART) on sexual behaviors and HIV-1 transmission risk has not been documented beyond the specific population of stable serodiscordant couples.

**Methods:** Based on a behavioral study nested in a randomized controlled trial (Temprano-ANRS12136) of early ART, we compared proportions of risky sex (unprotected sex with a partner of negative/unknown HIV status) reported 12 months after inclusion between participants randomized to initiate ART immediately ('early ART') or according to WHO criteria ('standard ART'). Group-specific HIV-transmission rates were estimated based on sexual behaviors and viral load-specific per-act HIV-1 transmission probabilities. Their ratio was computed to estimate the protective effect of early ART.

**Results:** Among 957 participants (baseline CD4: 478/mm$^3$), 46.0% reported sexual activity in the past month, 41.5% of them with non-cohabiting partners. Proportion of risky sex was 10.0% vs. 12.8%, respectively, in participants on early vs. standard ART ($p=0.17$). Accounting for sexual behaviors and viral load, the estimated protective effect of early ART was 90% (95% CI 81-95%).

**Conclusion:** Twelve months after inclusion, patients on early and standard ART reported similar sexual behaviors. Early ART decreased the estimated risk of HIV transmission by 90%, suggesting a major prevention benefit among both stable and casual partners.

**Key-words:** HIV prevention; antiretroviral treatment; sexual behaviors; HIV-1 sexual transmission; Treatment as Prevention; epidemiology; sub-Saharan Africa
Introduction

By controlling viral replication, antiretroviral therapy (ART) reduces the infectivity of HIV-positive patients, with some evidence that patients with an undetectable viral load (VL) have a negligible HIV-transmission risk [1,2]. In 2011, the HPTN052 trial demonstrated that initiating ART between 350-550 CD4, i.e. earlier than recommended by the World Health Organization (WHO) guidelines, had a 96% preventive effect against HIV transmission among stable serodiscordant couples [3]. This evidence strengthened the Treatment as Prevention (TasP) concept, under which providing ART to all HIV infected patients, regardless of their CD4 count, might decrease HIV transmission among the general population in such an extent that it would curtail the HIV pandemic [4,5]. Results of TasP randomized controlled trials are not expected before several years [6]. Meanwhile, there are still questions regarding factors that might impact the effect of early ART in the general population and make this effect different from that observed in the very specific group of stable serodiscordant couples.

Among these factors, the impact of early ART on risky sexual behaviors is one of major concern. In the first years of the highly active ART era, increased risky sexual behaviors associated with ART were reported among high-risk groups [7,8]. Risk compensation related to decrease in perception of HIV transmission risk and severity of HIV infection may potentially offset the protective effect of early ART [9,10]. Nevertheless, a recent review of observational studies conducted in developing countries rather suggested a decrease in risky sexual behaviors after ART initiation [11]. However, such studies may be subject to confounding. In addition, only few of them were prospective [12], and all were conducted in the context of standard ART initiation [11,13]. Starting ART earlier in healthy patients, may impact on sexual behaviors differently. Updating results about this issue, especially in the current context of early ART initiation, is thus needed [14].

Evidence obtained so far has resulted in WHO recommendations of early ART for prevention specifically for the population of serodiscordant couples [15]. Nevertheless, according to a recent estimation, only less than a third of new HIV transmissions in sub-Saharan Africa occurs among these couples [16]. This suggests that programs targeting solely stable serodiscordant couples may lack to prevent the majority of new infections. Estimating the preventive effect of early ART beyond the population of stable serodiscordant couples is thus of great interest for scaling-up effective prevention strategies.
Relying on data from the ongoing Temprano-ANRS12136 randomized controlled trial, we aimed to measure the impact of early ART initiation on sexual behaviors and to estimate its protective effect among a West African adult population reporting diverse heterosexual partnership status (serodiscordant or concordant, stable or casual).

**MATERIAL & METHODS**

**Temprano-ANRS12136 trial**

Temprano is a multicenter randomized open-label superiority trial to assess the benefits and risks of initiating ART earlier than currently recommended by WHO, concomitantly or not with a 6-month isoniazide prophylaxis for tuberculosis (IPT). The trial was launched in March 2008 in Abidjan, Côte d’Ivoire, and is still ongoing. The trial protocol was approved by the ethics committee of the Ministry of Health of Côte d’Ivoire and by the institutional review board of the French National Agency for Research on AIDS and viral hepatitis (ANRS, Paris, France). It has been registered on clinicaltrials.gov under the following identifier: NCT00495651.

Between March 2008 and July 2012, patients attending 9 care centers in Abidjan were included in the trial whenever they met the following criteria: signed informed consent; age>18 years; HIV-1 or HIV 1+2 dual infection; no ongoing active tuberculosis; no ongoing pregnancy or breastfeeding; CD4 count<800 cells/mm$^3$ and no criteria for starting ART according to the most recent WHO guidelines. Participants were randomized into four arms: two “standard ART” arms (arm 1 and 2), in which ART was delayed until patients meet ongoing WHO starting criteria[17,18]; and two “early ART” arms (arm 3 and 4), in which ART was initiated immediately on inclusion. In arm 2 and arm 4, participants received a 6-month IPT, starting at the Month-1 visit and stopping at the Month-7 visit. Once included, participants were asked to show up for trial scheduled visits every 3 months. CD4 count and plasma HIV-1 RNA (real-time PCR, Taq Man technology Abi Prism 7000, Applied Biosystems, detectability 300 copies/mL) were measured every 6 months. Each participant was to be followed during 30 months. The main outcome of the trial is the occurrence of a new episode of severe morbidity and any event leading to death.

**Socio-behavioral study**
The present socio-behavioral study was nested in the Temprano trial. All participants included in Temprano between January 1st 2009 and September 1st 2011 were eligible for the study. A standardized questionnaire was used to collect information on sexual behaviors. Participants completed this questionnaire face-to-face at the 12-month visit (M12).

**Study outcomes**

Sexual behaviors of interest included sexual activity and multiple partnerships in the past year, and characteristics of the last sexual intercourse (including date occurred in the past month/past year), type of partnership (cohabiting or not) and partner’s HIV status (unknown/negative/positive).

Risky sex at last sexual intercourse in the past month was defined as an unprotected intercourse with a partner of HIV negative/unknown status. Partner’s exposure to HIV infection was defined as risky sex associated with a measure of VL≥300 copies/mm$^3$ at the time of the intercourse, i.e. within a period ranging from 30 days before to 7 days after the date of completion of the socio-behavioral questionnaire.

For each sexually active participant, a HIV transmission risk for the last intercourse in the past month was calculated based on reported partner’s HIV status, condom use and VL measured at the time of the intercourse. Per-coital-act VL-specific probabilities of transmission were derived from a seroconversion study of HIV-discordant couples in eastern and southern Africa [19], using the following formula:

$$p = 1 - e^{-e^{-7.257 + 1.070 \times \log(\text{VL}) - 4 - 0.025 \times (\text{age} - 35)}}$$

where $p$ is the per-coital probability of HIV transmission (J.P. Hughes, personal communication).

Patients with undetectable VL were assigned a null transmission risk [2]. We attributed a 78% transmission risk reduction if condom was reported, and, for female participants, we considered each last sexual male partner as circumcised (96% of men actually are in Côte d’Ivoire [20]) and thus applied a 53% transmission risk reduction [19]. Partners with unknown HIV status were considered as HIV-uninfected. For a partner reported as HIV-positive, transmission risk was set to zero.

We estimated HIV-transmission rates at last sexual intercourse in the past month for both ART strategies by computing means of individual transmission risks, expressed per 10,000 sexually active individuals.
In order to estimate transmission rates in the whole studied population and not only among sexually active persons, we computed an additional estimation including participants sexually inactive in the past month, attributing them a null individual transmission risk.

**Statistical analysis**

Participants included in the Temprano trial between January 1st 2009 and September 1st 2011 were included in the analysis provided they completed the 12-monthsocio-behavioral questionnaire in due time (±3 months).

Analyses were conducted in intention to treat. Sexual behaviors of interest were compared between early ART and standard ART strategies using Chi-2 tests. The protective effect of the early ART strategy on HIV-transmission risk was based on the ratio of transmission rates.

To assess the robustness of our estimates, we conducted a range of sensitivity analyses, considering: (i) only participants with baseline CD4>350/mm$^3$; (ii) only those engaged in a cohabiting serodiscordant relationship; (iii) a non-null transmission probability for those having a VL<300 copies/mm$^3$[21]; (iv) an alternative dataset for VL-specific transmissions probabilities[22]; (v) a probability of 0.4 to be HIV-positive for a sexual partner with unknown serostatus; (vi) all participants as having a last unprotected intercourse with a HIV-negative partner.

All analyses were conducted using SAS version 9.3 (SAS Institute, Cary, North Carolina, USA). We computed 95% Confidence Intervals for expected transmission rates and protective effect of early ART using bootstrap (10,000 re-sampling).

**RESULTS**

**Study population**

Among the 1172 participants included in the Temprano trial between 1st January 2009 and 1st September 2011, 957 (81.7%) were included in the analyses (standard ART: 467; early ART: 490). Participants on early and standard ART attended a similar mean number of trial medical visits between enrollment and 12 months (standard ART: 5.9; early ART: 6.2).
The remaining 215 were excluded (standard ART: 123 vs. early ART: 92; p=0.03) for the following reasons: death within the first 12 months (6 vs. 9, respectively; p=0.42); not showing up for 12-month visit (17 vs. 38, respectively; p=0.003); 12-month socio-behavioral questionnaire not or untimely completed (standard ART: 93, of which 59 had initiated ART before the 12-month visit; early ART: 30; p=0.02).

Participants included in the study did not differ from those excluded regarding socio-demographic characteristics, except for schooling (at least secondary level: included 47.1%, excluded 38.1%; p=0.02).

Among the 957 participants, a large majority (80.4%) were women. At baseline, median age was 35 years and 442 participants (46.2%) were living in union. Neither baseline socio-demographic and clinical characteristics (Table 1) nor baseline VL distributions (Wilcoxon rank-sum test: 0.53; Figure 1a) significantly differed between participants on early vs. standard ART.

At the 12-month visit, 70 (15.0%) patients in standard ART had initiated ART (median duration between inclusion and ART initiation: 9.5 months). Overall, VL measured at 12-month was available for 427 (91.4%) patients on standard ART and 468 (95.5%) on early ART. As expected, due to the difference in ART coverage, the percentage of patients with undetectable VL was significantly lower in those on standard ART vs. early ART (Wilcoxon rank-sum test: p<10^-3; Figure 1b).

Sexual Behaviors, Risky Sex and Partner’s Exposure to HIV infection at 12-month visit

Sexual behaviors in the past 12 months are presented in Table 2. No significant difference was observed between patients on standard vs. early ART in the proportions of sexual activity (standard ART: 71.7% vs. early ART: 69.8%; p=0.51) and multiple partnerships (6.2% vs. 9.0%, respectively; p=0.11) in the past year. Among sexually active participants, 41.2% vs. 41.8%, respectively, reported they were not cohabiting with their last sexual partner (p=0.87). Overall, the last sexual partner was reported to be HIV-uninfected by 26.6% vs. 22.8% of sexually active participants, respectively; and to have an unknown HIV-status by 43.9% vs. 47.7%, respectively (p=0.47).

Characteristics of the last intercourse in the past month are presented in Table 3. Participants on standard vs. early ART did not significantly differ as regard to sexual activity in the past month and condom use. Risky sex was reported by 12.8% of participants in standard ART vs. 10.0% in early ART.
When taking into account last available VL, the proportions of participants exposing their partner to HIV infection were 10.7% vs. 2.4%, respectively (p<0.001).

Estimated HIV-transmission rates at 12-month visit

Figure 2a shows the estimated HIV-transmission rates per 10,000 sexually active persons at last sexual intercourse in the past month, based on risk behaviors and VL data, for both ART strategies. The estimated transmission rate was 4.0/10,000 (95% Confidence Interval, 95%CI: 3.0-5.0) among those on standard ART and 0.5/10,000 (95%CI: 0.2-0.8) among those on early ART. The corresponding estimated protective effect of early ART against HIV transmission was 89% (95%CI: 79-95%). When including all participants in the computations (Figure 2b), the estimated transmission rate was 1.9/10,000 (95%CI: 1.4-2.4) in those on standard ART vs. 0.2/10,000 (95%CI: 0.1-0.3) in those on early ART, representing a protective effect of 90% (95%CI: 81-95%).

Results of sensitivity analyses are presented in Table 4. Whereas estimates of transmission rates varied substantially across scenarios, the estimated protective effect of early ART remained robust (ranging from 84 to 90%).

Relying on the estimated distribution of coital frequency previously reported among serodiscordant couples [22], we assumed a monthly number of 8 sexual intercourses for those sexually active in the past month (zero for those inactive) and extrapolated the characteristics reported for the last intercourse to all intercourses. Based on this assumption and on our estimate of transmission rates at last sexual intercourse calculated in the whole studied population, we estimated that early ART, compared to a standard ART strategy, could prevent 13.4 (95%CI: 9.4-17.7) infections for 10,000 patients during the 12th month following early ART initiation. By extrapolating this monthly number to the whole M0-M12 period, we estimated that early ART could prevent 161 (95%CI: 113-212) infections for 10,000 patients in their first year of treatment (based on estimated incidence rate of 18.7 infections /10,000 persons-years [PY] in early ART and 179.0/10,000 PY in standard ART).

DISCUSSION

In this study, nested in an ongoing randomized trial of early ART, patients who started ART at high CD4 counts and those who delayed ART initiation until WHO criteria are met declared similar
sexual behaviors at 12 months. Early ART was estimated to decrease by 90% the risk of HIV transmission to partners. This estimated risk reduction, which accounted for well-identified determinants of HIV transmission including VL, sexual partnership, condom use and circumcision[19], was mainly attributable to differences in VL levels between patients on early vs. standard ART. In contrast with previous studies that demonstrated the protective effect of ART among the sole serodiscordant stable couples, these estimates were derived from a diverse population with a wide range of partnerships and of partners’ HIV status. More than half of our patients were not in a cohabiting relationship, and about two thirds of those sexually active reported a last partner with HIV-negative or unknown status.

The first very original finding of this study is about sexual behaviors in patients on early ART, which were comparable to those reported by patients on standard ART 12 months after inclusion. The sample size was large enough to allow the detection of a 5% difference (from 5% to 10%) between both ART strategies with a power of 0.95. Overall proportions of sexual activity in the past year (71%) and unprotection at last intercourse (25.4%) were consistent with figures previously reported in Côte d’Ivoire in patients treated at late stages of HIV infection [23–25]. To our knowledge, no data on sexual behaviors in the context of early ART has been published to date.

According to a recent review conducted in developing countries, decrease in unprotected sex was observed in 16 over 17 observational studies among patients on standard initiated treatment[11]. Such a decline in unprotected sex associated with ART may be explained by the multiple medical encounters that treated patients have with the care system, which ensures a high level of prevention counseling and psychosocial support [25,26]. In routine, contacts with the care system are often rare for patients non-eligible for ART [27]. In our study, participants in early and standard ART strategies both had a high frequency of contact with medical care, which may explain comparability in self-reported sexual behaviors. Because data reported in the standard ART initiation context show that sexual behaviors changes may occur over a long time period [28], sexual behaviors changes in relation with early ART initiation deserve to be further assessed on the long term.

We used three different indicators to estimate HIV-transmission risk and its reduction. First, the proportion of last sexual intercourses exposing the partner to HIV infection based on the plasma VL level. This proportion was significantly lower among participants on early vs. standard ART. Proportions of unprotected intercourses with serodiscordant partners regardless of VL level were
not significantly different between both ART strategies. This suggests that the protective effect of early ART compared to a standard strategy principally lies on the biological effect of the treatment on viral replication rather than on a combination of biological and behavioral effect, as suggested by others[11].

Our second estimate of HIV-transmission risk was the expected number of transmissions at last intercourse in the past month, combining sexual behavior (condom use, partner's HIV status, and circumcision), exact VL values and HIV-1 transmission probabilities from the literature[19]. This methodology has been recently used and showed consistent results as compared to a seroconversion study [29]. Based on it, we estimated a protective effect of early ART of 90%. The magnitude of the protective effect we found was remarkably consistent across populations considered in the analysis, changes in our assumptions and variations in the parameters (Table 4), arguing for the robustness of our estimate. Moreover, this protective effect was close to those estimated in the HPTN052 study (96%) [3] and in a systematic review of prospective studies among discordant couples (91%, 95%CI: 79-96%) [30].

Third, we assessed the protective effect of early ART by computing the number of infections averted yearly for 10,000 persons after one year of treatment, which we estimated between 113 and 212. Those results rely on strong assumptions regarding the frequency of sexual intercourses and the stability over time of the ART preventive effect in the first year of treatment. Despite the uncertainty surrounding these assumptions, our results are quite consistent with previous studies. The sensitivity analysis we conducted on the sub-sample of stable serodiscordant couples allowed us to estimate HIV-incidence rates which were in the same range than those reported by the HPTN052 study [3]. Moreover, a previous model estimated that providing early (350<CD4<500) ART to serodiscordant couples might be expected to avert 210 infections per 10,000 person-years on ART [31]. Our estimate of 161/10,000 is lower, which is consistent with the fact that our study included a broader population than serodiscordant couples, among which a substantial part (those sexually inactive and/or engaged in seroconcordant partnerships) do not benefit from the preventive effect of ART.

Our results were obtained in a population with early HIV diagnosis engaged in a 30-monthtrial. The sex ratio was unbalanced in favor of women, which reflects both the sex-specific prevalence of HIV (6.4% and 2.9%, respectively [20]) and delayed diagnosis among men, who have lower opportunities of early diagnoses than women in Côte d'Ivoire [32]. Even if participants of the present
study potentially constitute a compliant population engaged in a trial offering good care conditions, the proportion of viral suppression achievement in participants on early ART 12 months after enrollment (83%) was not dramatically higher than that documented in population-based studies throughout sub-Saharan Africa [33]. This suggests that our results are likely to be in the range of figures observed more widely in West-Africa.

Our study has some limitations.

First, the present behavioral study was nested in a randomized controlled clinical trial which primary objective was to measure the individual rather than collective benefits and risks of early ART. Thus, before the implementation of the 2012 WHO guidelines [15], our results were obtained in the absence of specific information message about the preventive effect of ART. The current study may therefore only partially address the issue of risk compensation. Further research questioning risk perception in the context of widely available information about preventive effect of early ART is needed, both among HIV-infected and uninfected people.

Second, the results of this study largely rely on self-reported sexual behaviors, which are potentially subject to social desirability bias. Over-report of condom use could lead to an underestimation of the estimated HIV transmission risks. However, since counseling and follow-up were similar between both ART groups, such a bias is unlikely to be differential and thus to have affected our estimate of the preventive effect of early ART.

Third, estimates of HIV transmission risk were based on the characteristics of the last sexual intercourse. This might have biased the analysis if the frequency of sexual intercourses differed between both groups, and/or if there were differences between groups in the extent to which the last sexual intercourse reflected overall sexual behaviors. Such differences are unlikely, though, given that both groups were comparable for various indicators, including sexual activity and multiple partnerships.

Fourth, differences between ART strategies in the proportion of non-response to the M12 questionnaire might have biased estimations of HIV-transmission risk. A lower proportion of participants on standard vs. early ART completed the questionnaire during the considered window period, i.e. between M9 and M15. Patients who completed the questionnaire out of this period were mostly individuals randomized to standard ART, who initiated ART during the first 12 months of follow-up, which rescheduled subsequent visits and questionnaire completions from the date of ART initiation. Compared to other patients on standard ART, patients who started treatment before the 12-month
visit probably had higher VL, and therefore higher infectiousness, in their pre-ART period; and then lower VL and infectiousness in their ART-period. When considering the whole M0-M12 period, excluding these patients may have led to limited bias in the estimates of the transmission risk among those on standard ART and of the protective effect of early ART. In addition, missing 12-month visit during the window period were more frequent among patients on early ART (38 vs. 17). In 2011, because of the political crisis faced by Côte d’Ivoire, the Temprano staff anticipated violence in Abidjan and predictable disruption of health services by giving in advance a higher stock of drugs to patients [34]. Thus, treated patients might have delayed their 12-month visit without being necessarily out of treatment.

Expanding ART coverage has resulted in decreased HIV incidence in South Africa [35], but other “natural experiments” showed limited effecton HIV transmission, especially when risk compensation was observed [36]. Community trials have started to formally assess the effect of early ART on HIV incidence, but their results will not be released before several years. Meanwhile, our results suggest a strong protective effect of early ART on HIV heterosexual transmission without any detectable effecton sexual behaviors. This effect was estimated in a population including substantial proportions of persons out of stable partnership or with a seroconcordant partner, thus closer to the whole HIV-infected population than previous studies restricted to stable serodiscordant couples. WHO has recently recommended early ART initiation for people living in serodiscordant couple [15]. The social acceptability and equity of prioritizing access to early ART to this population is questionable though [37]. Recent modeling studies on the contribution of HIV-transmissions occurring among stable serodiscordant couples to the global sub-Saharan HIV epidemics demonstrated that prevention interventions targeted solely on those couples may have a limited public health impact [16,38]. Our results provide evidence for the public health significance of early ART initiation among a wider segment of the HIV-infected population.

ACKNOWLEDGEMENTS

We are indebted to all patients who participated in this trial.
We gratefully acknowledge the valuable contributions of the SMIT, CeDReS, CEPREF, USAC, CIRBA, CNTS, La Pierre Angulaire, Hôpital Général Abobo, Formation Sanitaire Anonkoua Kouté, Centre de santé El Rapha, Programme PACCi team and INSERM U897 teams: Abanou Matthieu, Aman Adou, Anasthasie Yapo, Bombo Léontine, Célestin N’chot, Christian Kouadio, Djetouan Hugues, Djobi-Djo Edouard, Goly Jocelyn, Kassi Marie-Cécile, Koffi- N’Dri Aholi, Konan Sylvie, Konaté Mamadou, Kouadio Bertin, Kouamé Martin, Kouadio Victoire, Kouakou-Aboua Adrienne, Kouakou Yao, Kouamé Antoine, Kouamé Ferdinand, Kouamé Gérald, Labibi Georgette, Lokou Benjamin, Moh Jules, N’Dri Marie Julie, Nalourgou Tuo, N’Goran Brou, Nogbout Marie-Pascale, Orne-Gliemann Joanna, Kouadio Cheftin, Ouattara Minata, Oupoh Joséphine, Sidibé Abdelh, Siloué Bertine, Soro Adidiata, Tchehy Amah-Cécile, Yao Emile, Yao Juliette

We thank Gilead Sciences for the donation of Truvada®, and Merck Sharp & Dohme for the donation of Stocrin®

Members of the ANRS 12136 Temprano trial Group:

Clinical care in Abidjan, Côte d’Ivoire

- Service des Maladies Infectieuses et Tropicales (SMIT): Emmanuel Bissagnene, Serge Eholie (principal investigator), Gustave Nzunetu, Cyprien Rabe, Sidibé Baba.
- Centre Intégré de Recherches Biocliniques d’Abidjan (CIRBA): Olivier Ba-Gomis, Henri Chenal, Marcelle Daligou, Denise Hawerlander.
- Centre National de Transfusion Sanguine (CNTS): Lambert Dohoun, Seidou Konate, Albert Minga, Abo Yao.
- Centre de Prise en Charge et de Formation (CePReF): Eugène Messou, Amani Anzian, Joachim Gnokoro, Patrice Gouessé.
- La pierre angulaire: Madeleine Kadio-Morokro, Alain Kouadio, Sëna Gountodji, Ediga Yédjédy, Alexis Amian
- Hôpital Général Abobo Nord: Emmanuel Kouamé, Dominique Koua, Solange Amon, Laurent Dja-Beugré, Amadou Kouamé
- FSU Anonkoua kouté: Oyéounlé Makaïla, Mounkaila Oyébi, Stanislas Sodenougbo, Nathalie Mbakop
Centre de santé El Rapha: Babatundé Natanael, Babatundé Carolle, Gisèle Bléoué, Mireille Tchoutchedjem

*Biology:* Centre de Diagnostic et de Recherches sur le SIDA (CeDReS), CHU de Treichville, Abidjan, Côte d’Ivoire: Matthieu Kabran (bacteriologist), Arlette Emieme (monitor), André Inwoley (immunologist), Hervé Menan (parasitologist), Timothée Ouassa (bacteriologist), Thomas-d’Aquin Toni (virologist), Vincent Yapo (virologist); Service de Virologie, CHU Necker, Paris, France: Marie-Laure Chaix (virologist), Christine Rouzioux (virologist).

*Trial coordination team:* Programme PACCI, Abidjan, Côte d’Ivoire: Xavier Anglaret (principal investigator), Christine Danel (coordinator), Raoul Moh (coordinator), Romuald Konan (pharmacist), Anani Badjé (monitor), Jean Baptiste N’takpé (monitor), Gérard Menan Kouamé (monitor), Franck Bohoussou (data manager); Centre Inserm 897, Bordeaux, France: Delphine Gabillard (statistician), Jérôme Le Carrou (monitor).


*Trial Independent Data Safety Monitoring Board:* François-Xavier Blanc, Dominique Costagliola, Brigitte Autran, Ogobara Doumbia, Sinata Koula-Shiro, Souleymane Mboup, Yazdan Yazdanpanah

*Representatives of the French Agence Nationale de Recherches sur le SIDA (ANRS, Paris, France):* Jean-François Delfraissy, Brigitte Bazin, Claire Rekacewicz, Géraldine Colin.

**REFERENCES**


Figure 1: Distribution of plasma HIV-1 RNA, in log_{10} copies/ml by ART strategy. Expressed as Log_{10} (VL); **a) At baseline.** Standard ART: undetectable VL: 4.3%; detectable VL: mean(log_{10} copies/ml) [95%IC] = 4.60 [4.52-4.68]. Early ART: undetectable VL: 4.1% detectable VL: mean(log_{10} copies/ml) [95%IC] = 4.63 [4.55-4.71]. **b) 12 months after inclusion.** Standard ART: undetectable VL: 12.5%; detectable VL: mean(log_{10} copies/ml) [95%IC] = 4.68 [4.60-4.76]. Early ART: undetectable VL: 82.9% detectable VL: mean(log_{10} copies/ml) [95%IC] = 3.88 [3.66-4.11].

Footnotes: log_{10} (HIV-1 RNA) < 2.48 corresponds to the detectability threshold of HIV-1 RNA < 300 copies/mL.
Figure 2: Estimated HIV-transmission rates at last sexual intercourse in the last month, by ART strategy. Socio-behavioral study nested in the Temprano trial, M12 visit (N=957). a) for 10,000 sexually active participants, b) for 10,000 participants.

Footnotes: Per-act VL-specific transmission probabilities are derived from Hughes et al., 2012 [19]. Calculation accounted for sexual activity, condom use, circumcision and partner’s HIV status.
<table>
<thead>
<tr>
<th></th>
<th>Standard ART</th>
<th>Early ART</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=467</td>
<td>N=490</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>93 (19.91%)</td>
<td>94 (19.18%)</td>
<td>0.78</td>
</tr>
<tr>
<td>Women</td>
<td>374 (80.09%)</td>
<td>396 (80.82%)</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;30</td>
<td>118 (25.27%)</td>
<td>118 (24.08%)</td>
<td>0.30</td>
</tr>
<tr>
<td>30-40</td>
<td>217 (46.47%)</td>
<td>211 (43.06%)</td>
<td></td>
</tr>
<tr>
<td>&gt;40</td>
<td>132 (28.27%)</td>
<td>161 (32.86%)</td>
<td></td>
</tr>
<tr>
<td>Educational level</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>94 (20.13%)</td>
<td>131 (26.73%)</td>
<td>0.10</td>
</tr>
<tr>
<td>Primary</td>
<td>144 (30.84%)</td>
<td>137 (27.96%)</td>
<td></td>
</tr>
<tr>
<td>Secondary</td>
<td>170 (36.40%)</td>
<td>170 (34.69%)</td>
<td></td>
</tr>
<tr>
<td>&gt;Secondary</td>
<td>59 (12.63%)</td>
<td>52 (10.61%)</td>
<td></td>
</tr>
<tr>
<td>Personal source of income</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>116 (26.07%)</td>
<td>134 (28.33%)</td>
<td>0.44</td>
</tr>
<tr>
<td>Yes</td>
<td>329 (73.93%)</td>
<td>339 (71.67%)</td>
<td></td>
</tr>
<tr>
<td>Family status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single</td>
<td>200 (42.83%)</td>
<td>203 (41.43%)</td>
<td>0.52</td>
</tr>
<tr>
<td>Living in union</td>
<td>218 (46.68%)</td>
<td>224 (45.71%)</td>
<td></td>
</tr>
<tr>
<td>Separated/widowed</td>
<td>49 (10.49%)</td>
<td>63 (12.86%)</td>
<td></td>
</tr>
<tr>
<td>Perceived health</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Excellent/Very good</td>
<td>100 (21.69%)</td>
<td>99 (20.45%)</td>
<td>0.12</td>
</tr>
<tr>
<td>Good</td>
<td>298 (64.64%)</td>
<td>295 (60.95%)</td>
<td></td>
</tr>
<tr>
<td>Poor/Bad</td>
<td>63 (13.67%)</td>
<td>90 (18.60%)</td>
<td></td>
</tr>
<tr>
<td>WHO clinical stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>290 (62.10%)</td>
<td>310 (63.27%)</td>
<td>0.97</td>
</tr>
<tr>
<td>2</td>
<td>125 (26.77%)</td>
<td>124 (25.31%)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>50 (10.71%)</td>
<td>54 (11.02%)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>2 (0.43%)</td>
<td>2 (0.41%)</td>
<td></td>
</tr>
<tr>
<td>CD4 cell count /mm³</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;350</td>
<td>71 (15.2%)</td>
<td>88 (17.9%)</td>
<td>0.44</td>
</tr>
<tr>
<td>350-499</td>
<td>176 (37.7%)</td>
<td>187 (38.2%)</td>
<td></td>
</tr>
<tr>
<td>≥500</td>
<td>220 (47.1%)</td>
<td>215 (43.9%)</td>
<td></td>
</tr>
</tbody>
</table>
Table 2: Sexual behaviors in the past 12 months, by ART group. Socio-behavioral study nested in the Temprano trial, M12 visit (N=957).

<table>
<thead>
<tr>
<th></th>
<th>Standard ART</th>
<th>Early ART</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n (%)</td>
<td>n(%)</td>
<td></td>
</tr>
<tr>
<td><strong>Overall</strong></td>
<td>N=467</td>
<td>N=490</td>
<td></td>
</tr>
<tr>
<td>Sexually active in the past year</td>
<td>335 (71.7)</td>
<td>342 (69.8)</td>
<td>0.51</td>
</tr>
<tr>
<td>Multiple partnership</td>
<td>29 (6.2)</td>
<td>44 (9.0)</td>
<td>0.11</td>
</tr>
<tr>
<td><strong>Among those sexually active in the past year</strong></td>
<td>N=335</td>
<td>N=342</td>
<td></td>
</tr>
<tr>
<td>Last intercourse with a cohabiting partner</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>197 (58.8)</td>
<td>199 (58.2)</td>
<td>0.87</td>
</tr>
<tr>
<td>No</td>
<td>138 (41.2)</td>
<td>143 (41.8)</td>
<td></td>
</tr>
<tr>
<td>Last partner’s HIV status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV-negative</td>
<td>89 (26.6)</td>
<td>78 (22.8)</td>
<td>0.47</td>
</tr>
<tr>
<td>HIV-positive</td>
<td>99 (29.6)</td>
<td>101 (29.5)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>147 (43.9)</td>
<td>163 (47.7)</td>
<td></td>
</tr>
</tbody>
</table>

Table 3: Characteristics of the last intercourse in the past month, by ART group. Socio-behavioral study nested in the Temprano trial, M12 visit (N=957).

<table>
<thead>
<tr>
<th></th>
<th>Standard ART (N=467)</th>
<th>Early ART (N=490)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n (%)</td>
<td>n (%)</td>
<td></td>
</tr>
<tr>
<td>Last intercourse in the past month</td>
<td>226 (48.4)</td>
<td>214 (43.7)</td>
<td>0.14</td>
</tr>
<tr>
<td>Unprotected sex at last intercourse*</td>
<td>100 (21.4)</td>
<td>76 (15.5)</td>
<td>0.06</td>
</tr>
<tr>
<td>Risky sex¹ at last intercourse*</td>
<td>60 (12.9)</td>
<td>49 (10.0)</td>
<td>0.54</td>
</tr>
<tr>
<td>Partner’s exposure to HIV² at last intercourse*</td>
<td>50 (10.7)</td>
<td>12 (2.45)</td>
<td>&lt;10⁻³</td>
</tr>
</tbody>
</table>

* Last intercourse in the past month
¹ Unprotected sex with a partner of HIV-negative/unknown status
² Unprotected sex with a partner of HIV-negative/unknown status, and HIV viral load>300 copies/mL
Table 4: Sensitivity analyses of estimated HIV-transmission rates at last intercourse in the past month (per 10,000 persons) and estimated protective effect of early ART strategy. Socio-behavioral study nested in the Temprano trial, M12 visit (N=957).

<table>
<thead>
<tr>
<th>Population</th>
<th>Number of participants</th>
<th>Reference for VL-specific HIV transmission probabilities</th>
<th>Specific assumption</th>
<th>Expected HIV-transmissions at last sexual intercourse in the past month, for 10,000 persons [95%CI]</th>
<th>Protective effect [95%CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total sample</td>
<td>Standard arm: n=467; Early arm: n=490</td>
<td>Hughes et al. [19]</td>
<td>Main analysis</td>
<td>1.87 [1.39-2.39] 0.20 [0.09-0.33]</td>
<td>90% [81-95%]</td>
</tr>
<tr>
<td>Baseline CD4 count&gt;350</td>
<td>Standard arm: n=396; Early arm: n=402</td>
<td>Hughes et al. [19]</td>
<td>Same as in the main analysis</td>
<td>2.03 [1.47-2.66] 0.20 [0.08-0.36]</td>
<td>90% [81-96%]</td>
</tr>
<tr>
<td>Cohabiting serodiscordant couples</td>
<td>Standard arm: n=55; Early arm: n=54</td>
<td>Hughes et al. [19]</td>
<td>Same as in the main analysis</td>
<td>3.36 [2.11-4.78] 0.37 [0.14-0.64]</td>
<td>89% [77-96%]</td>
</tr>
<tr>
<td>Total sample</td>
<td>Standard arm: n=467; Early arm: n=490</td>
<td>Hughes et al. [19]</td>
<td>VL=300 copies/mL for patients with undetectable VL</td>
<td>1.88 [1.40-2.40] 0.30 [0.19-0.43]</td>
<td>84% [75-90%]</td>
</tr>
<tr>
<td>Total sample</td>
<td>Standard arm: n=467; Early arm: n=490</td>
<td>Gray et al. [22]</td>
<td>Same as in the main analysis</td>
<td>1.72 [1.36-2.11] 0.25 [0.14-0.4]</td>
<td>85% [75-92%]</td>
</tr>
<tr>
<td>Total sample</td>
<td>Standard arm: n=467; Early arm: n=490</td>
<td>Hughes et al. [19]</td>
<td>40% of partners with unknown HIV status considered as HIV-positive</td>
<td>1.34 [1.01-1.70] 0.13 [0.07-0.22]</td>
<td>90% [82-95%]</td>
</tr>
<tr>
<td>Total sample</td>
<td>Standard arm: n=467; Early arm: n=490</td>
<td>Hughes et al. [19]</td>
<td>All participants considered as having had a last unprotected intercourse with a HIV-negative partner</td>
<td>18.4 [16.6-20.3] 2.1 [1.4-2.9]</td>
<td>89% [84-92%]</td>
</tr>
</tbody>
</table>